Back to search results

Resiliency Intervention for ALS Patients and Care-Partners

This study is testing an intervention called Resilient Together ALS, which teaches coping skills like mindfulness to people recently diagnosed with Amyotrophic Lateral Sclerosis (ALS) and their main caregivers. The goal is to help manage the emotional distress that can come with an ALS diagnosis. You might be able to join if you are 18 or older, have been recently diagnosed with ALS (within about 2 months of your first appointment at the Healey Center), and can understand and communicate about the study. This study is looking to enroll up to 20 participants (10 pairs of patients and caregivers) to see if the intervention is practical and well-received. The information gathered will help improve the intervention for future use.

Study design
This is an interventional study with up to 20 participants. It is an open pilot study, meaning all participants will receive the intervention.
What's involved
You would participate in 6 sessions, each 30-45 minutes long, over Zoom. You will complete assessments at the beginning and after 6 weeks, and participate in an exit interview.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 6 weeks, with assessments at the beginning and end of this period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06968468

Resiliency Intervention for Patients With ALS and Their Care-Partners

Not Yet Recruiting
NAAges 18+InterventionalTreatment
Massachusetts General Hospital
~20 participants
Updated 2025-11-17 on ClinicalTrials.gov
What's tested:Resilient Together ALS

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recruitment Feasibility
Measured over 0 weeks
+6 more outcomes measured

Conditions

Amyotrophic Lateral Sclerosis (ALS)
Emotional Distress

Explore related trials

Amyotrophic Lateral Sclerosis

NCT06968468

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Massachusetts General Hospital

    Boston, Massachusettsno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Christina Rush, PhD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Who to contact

Christina Rush, PhD
[email protected]
617-643-7641
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

recent (within \~2 months) of first appointment at Healey Center for diagnosis of ALS documented in Epic (based on recommendations from neurologists)
ability to understand the study and research protocol as determined by a standardized teach-back method of assessment
ability to communicate by writing, speaking, or assistive communication device
English speaking adults
dyad lives together
at least one partner endorses clinically significant emotional distress during screening (\>7 on either subscale of the HADS)

Exclusion

patient with ALS with comorbid terminal diagnosis or severe mental health disorder that limits ability to participate (by self-report, as determined by our clinical team);
cognitive disorder that limits ability to participate (per neurologist)
inability or unwillingness to use live video technology (will teach any dyads who have low technology literacy how to use live video technology)

What this trial measures

  • Recruitment Feasibility0 weeks

    Percentage of eligible ALS patient-caregiver dyads that participate in the intervention (\>70% acceptable; \>80% excellent).

  • Data Collection FeasibilityPre-test (0 weeks) to Post-test (6 weeks)

    Percentage of dyads with no missing measures (\>70% acceptable; \>80% excellent)

  • Adherence Feasibility6 weeks

    Percentage of RT-ALS dyads that complete 4/6 sessions (\>70% acceptable; \>80% excellent)

  • Therapist Fidelity Feasibility6 weeks

    Percentage of adherence checklists completed; percentage of selected sessions (20%) with 100% adherence Fidelity Checks (\>70% acceptable; \>80% excellent).

  • Treatment Satisfaction6 weeks

    Percentage of dyads who score above the midpoint on Client Satisfaction Questionnaire (\> 70% acceptable; \> 80% excellent)

  • Credibility and ExpectancyPre-test (0 weeks)

    Percentage of dyads who score above midpoint on the Credibility/Expectancy Questionnaire (\> 70% acceptable; \> 80% excellent)

  • Adverse Events6 weeks

    None or minimal adverse events